Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, mesotherapy containing nutritional supplements was found to increase patient satisfaction and improve the number of hair follicles more effectively than topical minoxidil in treating female pattern hair loss, though both methods showed similar overall efficacy in hair density and hair loss reduction.

This observational study found that mesotherapy with neonatal mesenchymal stem cells led to mild hair growth improvement in 70% of patients with androgenetic alopecia, with no major adverse events reported.

This study used a network meta-analysis to compare alopecia areata treatments, finding that intralesional corticosteroids are most effective for mild cases, while diphenylcyclopropenone ranks highest for moderate to severe cases; further research on oral tofacitinib is needed.

In this study, intralesional triamcinolone acetonide injections were associated with halting the progression of frontal fibrosing alopecia in female patients and showed minimal adverse effects, but the efficacy as sole therapy remains unclear pending further trials.

This study found that combination therapy with PRP and minoxidil led to more significant improvement in androgenetic alopecia than either treatment alone, as confirmed by trichoscopic analysis.

In this study, the combination of topical minoxidil 5% and betamethasone valerate 0.1% achieved slightly higher depigmentation in vitiligo of hair-bearing areas but did not show significant improvement over betamethasone valerate alone.

Results are not reported for this review, which aimed to gather evidence on the effect of platelet-rich plasma monotherapy for androgenetic alopecia in men and women.

This study found that intralesional corticosteroids were most likely to produce a response in mild alopecia areata, while diphenylcyclopropenone was top-ranked for moderate to severe cases.

This review discusses emerging therapies for androgenetic alopecia, including topical finasteride, oral minoxidil, and intradermal dutasteride, and reports no clinical results; the authors highlight changes in treatment approaches.

This study observed that a mesotherapy formulation was associated with statistically significant improvements in hair quantity, thickness, and scalp condition among 23 patients with androgenetic alopecia, without noted side effects.

This study found that hair mesotherapy containing biomimetic peptides, vitamins, and micronutrients significantly improved hair parameters in patients with androgenetic alopecia and was well-tolerated over an 8-session treatment period.

In this case study, a 38-year-old woman with female androgenetic alopecia experienced improved hair density, reduced scalp oiliness, and enhanced hair structure after ten microneedle mesotherapy treatments combined with saw palmetto supplementation, with no adverse effects reported.

RF-mesotherapy with bicalutamide may be a promising new treatment for hair loss.

This study found that among various treatments for male androgenetic alopecia, dutasteride 0.5 mg/day was the most effective option overall. Additionally, among FDA-approved treatments, topical minoxidil 5% was the most effective topical therapy, and finasteride 1 mg/day was the most effective oral therapy.

Using truncal anesthesia on the supraorbital nerve reduces pain in hair loss treatments and improves patient comfort.

The book gives a basic overview of mesotherapy and fat-dissolving injections but lacks detailed guidance and effectiveness comparisons for practitioners.

This review summarizes the use of injectable dutasteride mesotherapy for androgenic alopecia and reports improved hair growth when combined with other substances, but highlights the need for further studies to establish long-term protocols.

This article discusses emerging therapies for androgenetic alopecia, highlighting the use of intradermal dutasteride, but it reports no new clinical findings.

Among patients treated at Thomas Jefferson University, this study found that adding cryotherapy to intralesional triamcinolone acetonide (IL TAC) was more effective at reducing keloid size compared to IL TAC alone, although both treatments similarly eased pruritus and pain.

This review discusses the expanding role of microneedling in dermatology, highlighting its enhanced effectiveness when combined with other treatments like minoxidil, platelet-rich plasma, and exosomes, but reports no clinical results.

This study reviewed contemporary literature and found that combining minoxidil with topical finasteride, biologic adjuvants, or delivery innovations might enhance treatment effectiveness for androgenetic alopecia compared to minoxidil alone, although diverse outcomes and incomplete data limit broader conclusions.

In this retrospective chart review, researchers observed that estrogen monotherapy effectively suppressed testosterone levels below 50ng/dL in all transfeminine patients studied, particularly those using injectable formulations, though the small sample size and ongoing data collection limit these findings.

In this retrospective study, among transfeminine patients aged 19-81 receiving gender-affirming estrogen therapy, 100% achieved testosterone suppression without anti-androgens when serum estradiol exceeded 100pg/mL, predominantly using injectable estrogen.

This article reviews alopecia areata treatments, noting varied outcomes, and reports no new clinical results.

This study investigated treatments for male androgenetic alopecia, finding that combining injectable platelet-rich fibrin (i-PRF) with microneedling increased hair growth more effectively than i-PRF alone according to questionnaires and photographic assessments.

In this study, tofacitinib monotherapy was effective in achieving hair regrowth in over half of Korean patients with moderate-to-severe and refractory alopecia areata, though treatment discontinuation typically led to hair loss recurrence.